Alexion Europe
7 products tracked · names used in filings: Alexion Europe, Alexion Europe SAS
Upcoming milestones
Mon 23 Nov 2026🇪🇺 Expected EC decisionestimatein 9 days
Klygefa (gefurulimab): expected EC decision
Estimated as CHMP opinion (2026-09-17) + 67 days, the standard Commission decision period. Not an official date. · Alexion Europe · source
Recent milestones
Fri 30 Oct 2026🇪🇺 Application withdrawn (EU)
Amlypave (anselamimab): EU application withdrawn
Thu 17 Sep 2026🇪🇺 CHMP positive opinion
Klygefa (gefurulimab): CHMP positive opinion
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Klygefa gefurulimab | Opinion | |
| 🇪🇺 | Amlypave anselamimab | Application withdrawn | |
| 🇪🇺 | Voydeya danicopan | Authorised | 2024-04-19 |
| 🇪🇺 | Ultomiris ravulizumab | Authorised | 2019-07-02 |
| 🇪🇺 | Kanuma sebelipase alfa | Authorised | 2015-08-28 |
| 🇪🇺 | Strensiq asfotase alfa | Authorised | 2015-08-28 |
| 🇪🇺 | Soliris eculizumab | Authorised | 2007-06-20 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.